Porter Health

2026 Cholesterol Guidelines

What the Latest ACC/AHA Guidelines Mean for Your Heart Health

Based on the 2026 ACC/AHA Guideline on the Management of Dyslipidemia

What Changed and Why It Matters

In 2026 the American College of Cardiology (ACC) and American Heart Association (AHA), along with 10 other major medical organizations, released a comprehensive update to cholesterol management guidelines. This replaces the 2018 guideline and reflects new evidence from large clinical trials and improved risk-prediction tools.

The Core Message:

Treat dyslipidemia (abnormal cholesterol) earlier in life, use more modern risk calculators, aim for specific LDL-C targets, and take advantage of new medications when lifestyle changes and statins alone aren't enough. The emphasis is on reducing lifelong exposure to cholesterol that damages your arteries.

Important: This guide is a consumer-friendly summary. Treatment decisions should always be made with your healthcare team based on your individual risk profile.

1. Start Young: Earlier Screening for Everyone

The guidelines strongly emphasize that cholesterol problems should be caught early in life, because the longer your arteries are exposed to high cholesterol, the greater your risk of heart attack and stroke.

Updated Screening Recommendations:

Children Ages 9-11

All children should be screened for cholesterol with a lipid profile between ages 9 and 11 to catch inherited conditions like familial hypercholesterolemia (FH), which affects 1 in 250 people.

Children with Family History

If a close relative has premature heart disease, very high cholesterol, or FH, screening should start as early as age 2.

Adults Starting at Age 19

All adults should begin regular lipid screening at age 19 and repeat at least every 5 years, with more frequent testing if you have additional risk factors.

Young Adults (Ages 18-39)

Even young adults should receive dietary, physical activity, and weight optimization recommendations to reduce cumulative cholesterol exposure and lifetime heart disease risk.

Why this matters: Mendelian randomization studies show that lifelong low LDL-C is associated with dramatically lower heart disease risk. The longer you keep cholesterol low, the better your protection.

2. A More Accurate Risk Calculator: PREVENT-ASCVD

The guidelines now recommend using the newer PREVENT-ASCVD equations (instead of the older Pooled Cohort Equations or PCE) to estimate your 10-year and 30-year risk of heart attack and stroke. The guideline describes this as the "CPR" approach:

Calculate

Estimate your 10-year ASCVD risk using PREVENT-ASCVD equations

Personalize

Consider individual factors not in the equations (family history, Lp(a), hsCRP, reproductive history, etc.)

Reclassify & Reassess

When uncertain, use a coronary artery calcium (CAC) score to refine your risk category and guide treatment decisions

New Risk Categories (Using PREVENT-ASCVD):

Low (<3%)

Focus on healthy lifestyle

Borderline (3% to <5%)

Consider risk enhancers; discuss statin therapy

Intermediate (5% to <10%)

Moderate-to-high intensity statin recommended

High (≥10%)

High-intensity statin therapy recommended

What's different? PREVENT-ASCVD estimates are about 40-50% lower than the old PCE for the same person, but the treatment thresholds have been lowered to match. More people will now qualify for statin therapy starting at a PREVENT-ASCVD risk of 3% or higher, compared to 5% or higher under the old PCE.

Special Risk Escalation Rules:

Borderline Risk + Inflammation

If your 10-year ASCVD risk is borderline (3-<5%) and your hsCRP (inflammation marker) is ≥2 mg/L on two separate occasions, the guidelines recommend escalating to high-intensity statin therapy. This recognizes that chronic inflammation significantly amplifies borderline cardiovascular risk.

Young Adults with Long-Term Risk

If you're between 30 and 59 years old with low 10-year risk (<3%) but your 30-year ASCVD risk is ≥10%, or your LDL-C is 160-189 mg/dL, the guidelines say it's reasonable to discuss starting a moderate-intensity statin. The idea is that decades of even mildly elevated cholesterol cause significant cumulative artery damage.

3. Know Your Goal: Specific LDL-C Targets Are Back

A major change in the 2026 guidelines is the return of specific LDL-C and non-HDL-C treatment goals. Instead of just aiming for a percentage reduction, your doctor now has a specific number to target based on your risk level.

LDL-C Goals by Risk Category:

Primary Prevention (No Prior Heart Disease)

Low risk (<3%): LDL-C <100 mg/dL through healthy lifestyle

Borderline to intermediate (3% to <10%): LDL-C <100 mg/dL and non-HDL-C <130 mg/dL

High risk (≥10%): LDL-C <70 mg/dL and non-HDL-C <100 mg/dL

Severe High Cholesterol (LDL-C ≥190 mg/dL)

Without FH or extra risk factors: LDL-C <100 mg/dL and non-HDL-C <130 mg/dL

With FH, extra risk, or subclinical disease: LDL-C <70 mg/dL and non-HDL-C <100 mg/dL

Already Have Heart Disease (Secondary Prevention)

Not at very high risk: LDL-C <70 mg/dL and non-HDL-C <100 mg/dL

At very high risk: LDL-C <55 mg/dL and non-HDL-C <85 mg/dL

Bottom line: Lower is better when it comes to LDL-C. The benefits of keeping LDL-C low grow over time, which is why the guidelines emphasize starting treatment earlier and maintaining it consistently.

4. New Tests to Know About: ApoB and Lp(a)

The 2026 guidelines place new emphasis on two additional blood tests beyond the standard lipid panel:

Apolipoprotein B (ApoB)

ApoB directly measures the number of "bad" cholesterol particles in your blood. Sometimes your LDL-C number looks fine, but you actually have too many harmful particles. This is especially common in people with diabetes, CKM syndrome, or high triglycerides.

When to test: After you've reached your LDL-C goal, measuring ApoB can help determine if you need additional therapy.

Lipoprotein(a) [Lp(a)]

Lp(a) is a genetically determined risk factor. Levels above 125 nmol/L (50 mg/dL) are associated with increased heart disease risk. Since Lp(a) levels don't change much over your lifetime, a single measurement is usually sufficient.

New recommendation: All adults should have Lp(a) measured at least once for ASCVD risk assessment. Elevated Lp(a) is considered a risk enhancer and may prompt earlier or more aggressive treatment.

5. Medications: A Broader Toolkit

Statins remain the cornerstone of cholesterol treatment, but the 2026 guidelines emphasize that combination therapy can achieve much lower LDL-C levels when needed.

Medication Tiers:

First Line: Statins

High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) lower LDL-C by ≥50%. Moderate-intensity statins lower LDL-C by 30-49%. Statins are safe, effective, and backed by decades of clinical trial evidence.

Second Line: Ezetimibe — Add It Earlier

Can be added to a statin to lower LDL-C by an additional 18-25%. Key change: The 2026 guidelines recommend adding ezetimibe as soon as you're not at your LDL-C goal on a statin — you no longer need to maximize the statin dose first. This is important because statin side effects are dose-dependent, so combining a moderate-dose statin with ezetimibe can be better tolerated than a high-dose statin alone. Available as a low-cost generic.

Third Line: PCSK9 Inhibitors & Bempedoic Acid

PCSK9 inhibitors (evolocumab, alirocumab) are injectable medications that lower LDL-C by 45-64%. Bempedoic acid is an oral option that lowers LDL-C by 17-24% and is especially useful for people who can't tolerate statins (it works in the liver, not muscles).

Newer Option: Inclisiran

A small-interfering RNA (siRNA) therapy given as an injection every 6 months that lowers LDL-C by 48-52%. An option for those who have trouble with more frequent injections.

What About Supplements?

The 2026 guidelines explicitly state that dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice) are not recommended for lowering LDL-C or triglycerides based on limited and inconsistent evidence. FDA-approved prescription medications are far more effective and well-studied.

6. Live Well: Lifelong Heart-Healthy Habits

Healthy lifestyle habits remain the foundation of all cholesterol treatment, at every risk level. The guidelines give healthy lifestyle a Class 1 (strongest) recommendation.

Heart-Healthy Diet

Emphasize fruits, vegetables, nuts, legumes, whole grains, and fiber. Replace saturated and trans fats with unsaturated fats (olive oil, fish, avocados). Mediterranean, DASH, and vegetarian diets have the strongest evidence.

Regular Physical Activity

At least 150 minutes/week of moderate-intensity aerobic exercise (or 75 minutes vigorous), plus 2 days/week of resistance exercise. Activity improves HDL-C, lowers triglycerides, and enhances insulin sensitivity.

Maintain a Healthy Weight

If overweight, a 5-10% weight loss can meaningfully improve lipid profiles. Weight management is especially important for lowering triglycerides.

Avoid Tobacco & Limit Alcohol

Smoking cessation improves HDL-C and overall cardiovascular health. Alcohol raises triglycerides and should be limited or eliminated, especially in those with elevated TG levels.

Even with genetic risk: Studies show that healthy lifestyle habits can reduce cardiovascular risk by approximately 50%, even in people who are genetically predisposed to heart disease.

7. Stay Consistent: Treatment Benefits Grow Over Time

The guidelines emphasize that cholesterol management is a lifelong commitment. Benefits accumulate the longer you maintain lower cholesterol levels.

Monitoring Schedule:

4-12 weeks after starting or changing medication: Recheck your lipid panel to assess response

Every 6-12 months thereafter: Continue monitoring to ensure you're at goal and adhering to therapy

Every 5 years (if not on medication): Routine lipid screening for adults with normal levels

Don't stop medications without consulting your doctor. The benefits of cholesterol-lowering therapy continue as long as you take the medication. Stopping statins has been associated with increased cardiovascular events.

8. Special Considerations

The 2026 guidelines include expanded guidance for specific groups:

Diabetes

Adults ages 40-75 with diabetes should be on at least moderate-intensity statin therapy. Those with multiple risk factors may benefit from high-intensity statins with a goal of LDL-C <70 mg/dL.

Coronary Artery Calcium (CAC) Scoring — Now with Specific LDL-C Goals

For the first time, the guidelines assign specific LDL-C targets based on your CAC score. This replaces the previous approach of just using CAC for risk reclassification.

CAC = 0: Defer statin therapy, reassess in 3-7 years. Very low near-term risk.

CAC 1-99: LDL-C <100 mg/dL, non-HDL-C <130 mg/dL. Moderate-intensity statin.

CAC 100-299 (or ≥75th percentile): LDL-C <70 mg/dL, non-HDL-C <100 mg/dL. High-intensity statin.

CAC 300-999: LDL-C <70 mg/dL (consider <55), non-HDL-C <100 mg/dL. High-intensity statin + consider add-on therapy.

CAC ≥1000: LDL-C <55 mg/dL, non-HDL-C <85 mg/dL. High-intensity statin + add-on therapies strongly recommended.

Women & Reproductive Risk Markers

Early menopause (<45 years), preeclampsia, gestational diabetes, and other adverse pregnancy outcomes are now recognized as risk enhancers that should factor into ASCVD risk assessment.

Chronic Kidney Disease (CKD Stage 3+)

Adults ages 40-75 with CKD and elevated LDL-C are recommended moderate-intensity statin or statin + ezetimibe combination to reduce ASCVD risk.

People Living with HIV

Statin therapy (specifically pitavastatin) is recommended for ages 40-75 on stable antiretroviral therapy to reduce the elevated cardiovascular risk seen in this population.

Older Adults (≥75 years)

Treatment decisions should balance ASCVD prevention with patient priorities, functional status, life expectancy, and potential for medication side effects. A benefit-risk discussion is essential.

Questions to Keep in Mind as You Discuss These Guidelines with Your Porter Health Coach or Medical Care Team

Key Takeaways

Start screening earlier: all children ages 9-11 and all adults from age 19, with repeat testing at least every 5 years

Use the PREVENT-ASCVD calculator for more accurate 10-year (and 30-year) risk estimates

LDL-C and non-HDL-C goals are back: your target depends on your risk category, from <100 mg/dL (low risk) down to <55 mg/dL (very high risk)

Get Lp(a) tested at least once in your lifetime — it's a genetically determined risk factor you can't find on a standard lipid panel

Statins are still first-line, but combination therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid) can achieve much lower LDL-C levels when needed

CAC scores now have specific LDL-C targets: CAC 0 means you can likely defer statins; CAC ≥100 means high-intensity treatment

If you're at borderline risk (3-5%) with elevated inflammation (hsCRP ≥2), consider high-intensity statin therapy

Young adults (30-59) with low 10-year risk but high 30-year risk (≥10%) should discuss starting a statin early

Dietary supplements are not recommended for cholesterol lowering — use proven medications instead

Healthy lifestyle remains the foundation at every risk level — diet, exercise, weight management, and not smoking

The benefits of cholesterol-lowering therapy grow over time — start earlier and stay consistent

Talk to your healthcare team about whether you need a CAC score, ApoB, or Lp(a) testing to refine your treatment plan

References:

Based on the 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia, published in the Journal of the American College of Cardiology. This guide translates the latest clinical recommendations into patient-friendly language to help you understand and manage your cholesterol.

Blumenthal RS, Morris PB, Gaudino M, Johnson HM, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016

This guideline retires and replaces the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.